The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer

M. Dowsett, J. S. Tobias, A. Howell, G. M. Blackman, H. Welch, N. King, R. Ponzone, M. Von Euler, M. Baum

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Thirty-four post-menopausal women with early breast cancer who had received 20 mg tamoxifen once daily as adjuvant therapy for at least 10 weeks participated in a randomized, double-blind, parallel-group, multicentre trial. The primary aim of the trial was to determine the effect of anastrozole upon tamoxifen pharmacokinetics, with secondary aims of assessing the tolerability of the two drugs in combination and whether or not tamoxifen had any effect upon the oestradiol suppression seen with anastrozole. Patients were randomized to receive either 1 mg anastrozole (16 patients) or matching placebo (18 patients) once daily on a double-blind basis for 28 days. No significant difference (P = 0.919) was observed in serum tamoxifen concentrations between the anastrozole and placebo groups during the trial. The serum concentration of oestradiol was significantly suppressed (P <0.0001) in patients co-administered anastrozole compared with placebo in the presence of tamoxifen, confirming that anastrozole remained an effective suppressant of oestradiol in the presence of tamoxifen. The combination of tamoxifen and anastrozole was well tolerated, with very little difference in side-effects reported between anastrozole and placebo. In conclusion, the results of this study confirm that anastrozole does not affect the pharmacokinetics of tamoxifen when the two drugs are given in combination to post-menopausal women with early breast cancer. In addition, the oestradiol suppressant effects of anastrozole appear unaffected by tamoxifen.

Original languageEnglish
Pages (from-to)311-315
Number of pages5
JournalBritish Journal of Cancer
Volume79
Issue number2
Publication statusPublished - 1999

Fingerprint

Tamoxifen
Pharmacokinetics
Breast Neoplasms
Estradiol
Placebos
anastrozole
Drug Combinations
Serum
Multicenter Studies

Keywords

  • Arimidex
  • Aromatase inhibitor
  • Breast cancer
  • Oestradiol
  • Oestrogen
  • Tamoxifen

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Dowsett, M., Tobias, J. S., Howell, A., Blackman, G. M., Welch, H., King, N., ... Baum, M. (1999). The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer. British Journal of Cancer, 79(2), 311-315.

The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer. / Dowsett, M.; Tobias, J. S.; Howell, A.; Blackman, G. M.; Welch, H.; King, N.; Ponzone, R.; Von Euler, M.; Baum, M.

In: British Journal of Cancer, Vol. 79, No. 2, 1999, p. 311-315.

Research output: Contribution to journalArticle

Dowsett, M, Tobias, JS, Howell, A, Blackman, GM, Welch, H, King, N, Ponzone, R, Von Euler, M & Baum, M 1999, 'The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer', British Journal of Cancer, vol. 79, no. 2, pp. 311-315.
Dowsett, M. ; Tobias, J. S. ; Howell, A. ; Blackman, G. M. ; Welch, H. ; King, N. ; Ponzone, R. ; Von Euler, M. ; Baum, M. / The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer. In: British Journal of Cancer. 1999 ; Vol. 79, No. 2. pp. 311-315.
@article{35812666c4f348c48ecd00a4855e5e0c,
title = "The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer",
abstract = "Thirty-four post-menopausal women with early breast cancer who had received 20 mg tamoxifen once daily as adjuvant therapy for at least 10 weeks participated in a randomized, double-blind, parallel-group, multicentre trial. The primary aim of the trial was to determine the effect of anastrozole upon tamoxifen pharmacokinetics, with secondary aims of assessing the tolerability of the two drugs in combination and whether or not tamoxifen had any effect upon the oestradiol suppression seen with anastrozole. Patients were randomized to receive either 1 mg anastrozole (16 patients) or matching placebo (18 patients) once daily on a double-blind basis for 28 days. No significant difference (P = 0.919) was observed in serum tamoxifen concentrations between the anastrozole and placebo groups during the trial. The serum concentration of oestradiol was significantly suppressed (P <0.0001) in patients co-administered anastrozole compared with placebo in the presence of tamoxifen, confirming that anastrozole remained an effective suppressant of oestradiol in the presence of tamoxifen. The combination of tamoxifen and anastrozole was well tolerated, with very little difference in side-effects reported between anastrozole and placebo. In conclusion, the results of this study confirm that anastrozole does not affect the pharmacokinetics of tamoxifen when the two drugs are given in combination to post-menopausal women with early breast cancer. In addition, the oestradiol suppressant effects of anastrozole appear unaffected by tamoxifen.",
keywords = "Arimidex, Aromatase inhibitor, Breast cancer, Oestradiol, Oestrogen, Tamoxifen",
author = "M. Dowsett and Tobias, {J. S.} and A. Howell and Blackman, {G. M.} and H. Welch and N. King and R. Ponzone and {Von Euler}, M. and M. Baum",
year = "1999",
language = "English",
volume = "79",
pages = "311--315",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer

AU - Dowsett, M.

AU - Tobias, J. S.

AU - Howell, A.

AU - Blackman, G. M.

AU - Welch, H.

AU - King, N.

AU - Ponzone, R.

AU - Von Euler, M.

AU - Baum, M.

PY - 1999

Y1 - 1999

N2 - Thirty-four post-menopausal women with early breast cancer who had received 20 mg tamoxifen once daily as adjuvant therapy for at least 10 weeks participated in a randomized, double-blind, parallel-group, multicentre trial. The primary aim of the trial was to determine the effect of anastrozole upon tamoxifen pharmacokinetics, with secondary aims of assessing the tolerability of the two drugs in combination and whether or not tamoxifen had any effect upon the oestradiol suppression seen with anastrozole. Patients were randomized to receive either 1 mg anastrozole (16 patients) or matching placebo (18 patients) once daily on a double-blind basis for 28 days. No significant difference (P = 0.919) was observed in serum tamoxifen concentrations between the anastrozole and placebo groups during the trial. The serum concentration of oestradiol was significantly suppressed (P <0.0001) in patients co-administered anastrozole compared with placebo in the presence of tamoxifen, confirming that anastrozole remained an effective suppressant of oestradiol in the presence of tamoxifen. The combination of tamoxifen and anastrozole was well tolerated, with very little difference in side-effects reported between anastrozole and placebo. In conclusion, the results of this study confirm that anastrozole does not affect the pharmacokinetics of tamoxifen when the two drugs are given in combination to post-menopausal women with early breast cancer. In addition, the oestradiol suppressant effects of anastrozole appear unaffected by tamoxifen.

AB - Thirty-four post-menopausal women with early breast cancer who had received 20 mg tamoxifen once daily as adjuvant therapy for at least 10 weeks participated in a randomized, double-blind, parallel-group, multicentre trial. The primary aim of the trial was to determine the effect of anastrozole upon tamoxifen pharmacokinetics, with secondary aims of assessing the tolerability of the two drugs in combination and whether or not tamoxifen had any effect upon the oestradiol suppression seen with anastrozole. Patients were randomized to receive either 1 mg anastrozole (16 patients) or matching placebo (18 patients) once daily on a double-blind basis for 28 days. No significant difference (P = 0.919) was observed in serum tamoxifen concentrations between the anastrozole and placebo groups during the trial. The serum concentration of oestradiol was significantly suppressed (P <0.0001) in patients co-administered anastrozole compared with placebo in the presence of tamoxifen, confirming that anastrozole remained an effective suppressant of oestradiol in the presence of tamoxifen. The combination of tamoxifen and anastrozole was well tolerated, with very little difference in side-effects reported between anastrozole and placebo. In conclusion, the results of this study confirm that anastrozole does not affect the pharmacokinetics of tamoxifen when the two drugs are given in combination to post-menopausal women with early breast cancer. In addition, the oestradiol suppressant effects of anastrozole appear unaffected by tamoxifen.

KW - Arimidex

KW - Aromatase inhibitor

KW - Breast cancer

KW - Oestradiol

KW - Oestrogen

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=0032943956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032943956&partnerID=8YFLogxK

M3 - Article

C2 - 9888474

AN - SCOPUS:0032943956

VL - 79

SP - 311

EP - 315

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 2

ER -